Arcturus Therapeutics ARCT 深 滬
等待開盤 08-07 09:30:00 美东时间
12.21
+0.380
+3.21%
華盛通- 最 高12.30
- 今 開11.80
- 成交量 41.25万股
- 最 低 11.435
- 昨 收 11.83
- 總市值 3.31亿
- 52周最高 25.88
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 8.04
- 委 比 -88.33%
- 總股本 2712.06万
- 歷史最高 129.71
- 量 比 1.10
- 振 幅 7.31%
- 歷史最低 4.11
- 每 手 1
- 風險率 3.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News
https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research
08-05 00:40
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report second quarter 2025 financial results and provide a business update on August 6, 2025. A conference call and webcast will be held at 4:30 p.m. ET the same day, and the webcast will be available on the Company’s website. Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases with a portfolio of advanced targeted topicals.
07-23 20:00
中信博与上海电气签署沙特2.3GW光伏项目大单，持续领跑中东市场
日前，中信博与上海电气正式签署沙特Sadawi光伏项目合作订单，项目容量2.3GW。上海电气电站工程公司总经理裘名华，中信博董事长蔡浩、高级副总裁周石俊等共同见...
07-17 09:54
William Blair Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)
In a report released today, Myles Minter from William Blair reiterated a Buy ra...
07-06 01:55
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
Chip Rossi Appointed to Artesian Resources Board of Directors
Artesian Resources Corporation announced the appointment of Salvatore J. "Chip" Rossi to its Board of Directors. Rossi, a financial expert with extensive experience in risk management, recently retired from Bank of America, where he held leadership roles including President of Bank of America Delaware and Head of Prepaid Card Unemployment Programs. His expertise in financial management and risk oversight, along with his deep understanding of the ...
07-01 17:30
Arcturus Therapeutics Reveals Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase Deficiency Program
ARCT-810 significantly and consistently reduces biomarker glutamine to levels within normal range15N-ureagenesis data provide first evidence of an mRNA therapeutic improving urea cycle functionAmmonia remained stable and
06-30 23:04
参股公司中昊芯英成长动力充足，科德教育有望打开业绩增长新空间
中昊芯英拥有行业领先的核心知识产权体系与资质认证，研发人员占比70%以上，其近两年业绩增长速度显著高于同行业其他公司。 2024年，科德教育（300192....
06-23 07:40
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 72,000 restricted stock units to nine new employees, vesting over four years, as inducement under the 2022 Plan, per Nasdaq rules. The units vest annually, contingent on continued employment. Arcutis focuses on innovative treatments for immune-mediated dermatological diseases.
06-06 20:00
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
